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A novel role for autologous tumour cell vaccination in the 
immunotherapy of the poorly immunogenic Bl6-BL6 
melanoma 
J. D. GEIGER, P. D. WAGNER, S. SHU AND A. E. CHANG 
Division of Surgical Oncology, Department of Surgery, University of Michigan, Ann Arbor, M/48109, USA 
The growth of immunogenic tumours stimulates the generation of tumour-sensitized, 
but not functional, pre-effector T cells in the draining lymph nodes. These pre-effector 
cells can mature into effector cells upon in-vitro stimulation with anti-CD3 and IL-2. In 
the current study, using a defined, poorly immunogenic tumour, B16-BL6 melanoma, 
the pre-effector cell response was not evident during progressive tumour growth but 
was elicited by vaccination with irradiated tumour cells admixed with Corynebacterium 
parvum. After anti-CDB/IL9 activation, these cells were capable of mediating the 
regression of established pulmonary metastases. The efficacy of the vaccine depended 
on the doses of both tumour cells and the adjuvant. While higher numbers of tumour 
cells were more effective, an optimal dose (12.5 pg) of C. parvum was required. The 
dose of irradiation was not a critical factor. After vaccination, kinetic studies revealed 
that the pre-effector cell response was evident 4 days later and declined after 14 days. 
These observations illustrate the potential role of active immunization in the cellular 
therapy of cancer. Surgical Oncology 1992; 1: 199-208. 
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INTRODUCTION 
Central to tumour immunology is the question of 
whether antigens recognizable by the host immune 
system exist on the surface of tumour cells. Clearly, 
definable tumour-specific antigens can be demon- 
strated in many animal tumour models [I, 21. These 
studies suggest the existence of similar antigens on 
human cancer cells and stimulated multiple 
attempts over the course of the last three decades 
to immunize patients with their own tumours [3-51. 
Most of these studies were performed empirically 
with little evidence of a specific immune response. 
Studies on immunological mechanisms of tumour 
rejection have identified the cellular effector arm of 
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the immune system as crucial in mediating tumour 
destruction. In fact, in a variety of animal models, 
the transfer of specifically tumour-sensitized 
lymphocytes to the tumour-bearing host can 
mediate therapeutic effects in rejecting established 
localized and metastatic cancers [6-81. Although 
theoretically attractive, this adoptive immunotherapy 
approach has received relatively little attention in 
humans because of difficulties associated with 
generating large numbers of correctly sensitized 
autologous cells. The application of adoptive 
immunotherapy for the treatment of human cancer 
therefore requires the development of methods to 
isolate and propagate in-vitro antitumour-reactive 
T-cells from patients. One potential cell source, 
which is suitable for adoptive immunotherapy, has 
been tumour-infiltrating lymphocytes (TIL), owing to 
the demonstration of their potent antitumour prop- 
erties in animal experiments [9, IO]. While the thera- 
peutic efficacy of human TIL expanded with IL-2 is 
being intensively evaluated in clinical trials, initial 
results are encouraging [I I]. 
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In the past few years, we have developed an 
additional method to generate large quantities of 
immune effector cells from the tumour-bearing host. 
The initial observations were made with several 
immunogenic murine tumours that during progres- 
sive tumour growth, draining lymph nodes (LN) 
were found to contain tumour-sensitized T-cells 112, 
131. Although these LN cells did not express overt 
antitumour reactivity, they could be further sensi- 
tized in vitro with anti-CD3 and IL-2 to differentiate 
into functional immune effector cells capable of 
mediating immunologically specific regression of 
established pulmonary metastases in adoptive 
immunotherapy [14-161. As immune effector cells 
could only be generated from tumour-bearing but 
not normal mice, the cells in the draining LN were 
therefore termed ‘pre-effector’ cells. However, due 
to several characteristics of the pre-effector cell 
response, extrapolation of these studies in the 
design of clinical adoptive immunotherapy in 
humans is difficult. First, the presence of pre- 
effector cells within LN draining progressive 
tumours follow rather strict kinetics depending on 
the duration of tumour growth [15]. Clinically, the 
duration of tumour growth in patients is variable at 
the time of presentation and is difficult to assess. 
Secondly, the pre-effector cell response and sub- 
sequent generation of therapeutic anti-CD3/lL-2 
activated effector cells has been defined only in the 
context of immunogenic tumours. The immunogeni- 
city of human tumours is not clear and is pre- 
sumably weak due to their spontaneous origin [17]. 
Hence, human tumours may elicit a weak pre- 
effector response. 
Therefore, we have selected the poorly immuno- 
genic murine B16-BL6 (BL6) melanoma to define 
clinically applicable methods to generate anti-CD3/ 
IL-2 activated effector cells for adoptive immuno- 
therapy. This tumour failed to induce systemic 
immunity by a variety of active immunization pro- 
cedures; and indeed we found that the progressive 
growth of the BL6 tumour did not elicit a detectable 
pre-effector cell response. However, pre-effector 
cells were generated in the draining LN in response 
to priming the host with tumour cells admixed with 
the bacterial adjuvant, Corynebacteriurn parvum (C. 
parvum). We have further demonstrated that 
vaccination of the host with irradiated tumour cells, 
admixed with C. parvum, was effective in eliciting a 
pre-effector cell response. In contrast to unirradiated 
BL6 tumour cells to prime the host, irradiated 
tumour cells lacked tumourigenicity and hence can 
be easily adapted for clinical use. We therefore have 
systematically defined the conditions and require- 
ments for the use of an effective vaccine in the BL6 
melanoma model. These studies suggest that a 
component of active immunization can facilitate the 
production of specific tumour-immune lymphocytes 
for adoptive immunotherapy and may be applicable 
in the treatment of human malignancy. 
MATERIALS AND METHODS 
Mice 
Female C57BL/6J (B6) mice, 6-8 weeks old, were 
purchased from the Jackson Laboratory, Bar Harbor, 
ME. They were maintained in specific pathogen-free 
environments and were used for experiments at the 
age of 10 weeks or older. 
Tumour 
The B16-BL6 (BL6) melanoma is a tumour of spon- 
taneous origin syngeneic to the B6 mouse that has 
been studied extensively [18, 191. The tumour was 
kindly provided by Dr E. Gorelik (University of Pitts- 
burgh), and was an early passage of the original BL6 
described by Hart [18]. Tumour cells were main- 
tained by in-vitro passage in complete media (CM). 
CM consisted of RPM1 1640 medium supplemented 
with 10% heat-inactivated fetal calf serum, 0.1 mM 
non-essential amino acids, 1 PM sodium pyruvate, 
2 mM fresh L-glutamine, 100 pg ml-’ streptomycin, 
1000 ml-’ penicillin, 50 pg ml-’ gentamicin, 0.5 pug 
ml-’ fungizone (all from GIBCO, Grand Island, NY) 
and 5 X 10e5 M 2-mercaptoethanol (Sigma). Cultured 
tumour cells were harvested after a short incubation 
at 37°C with a solution containing 0.25% trypsin and 
0.02% EDTA (GIBCO). Tumour cells were washed 
with Hanks Balanced Salt Solution (HBSS) prior to 
intravenous (i.v.) or subcutaneous (s.c.) inoculation. 
IL-2 
Human rlL-2 was kindly supplied by the Cetus Corp. 
(Emeryville, CA) with a specific activity of 6-8 x IO” 
Cetus U mg-’ protein. In this report, all units of IL-2 
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are expressed in Cetus units where 1 Cetus unit is 
equivalent to 6 international units. 
Anti-CD3 mAb 
The YCDSI hybridoma cells producing rat lgG26 
monoclonal antibody (mAb) directed against the 
CD3.r chain of the murine TCR/CD3 complex were 
produced and kindly provided by Dr Kim Bottomly, 
Yale University [20]. Antibodies were obtained by 
injecting hybridoma cells into pristane-primed sub- 
lethally irradiated (500 rad) DBA/2 mice and collect- 
ing ascites. The IgG content was determined by 
ELISA assay. 
Draining LN cells 
Tumour growth was initiated by inoculating syn- 
geneic B6 mice S.C. in the flank with 1 X IO6 viable 
BL6 admixed with various doses of C. parvum 
(Burroughs Wellcome Co., Research Triangle Park, 
NC) suspended in 0.05 ml of HBSS. In this case, 
tumour growth was evident at day 3. Tumour 
vaccine was prepared using irradiated tumour cells 
admixed with various doses of C. parvum and 
inoculated into syngeneic mice similarly. Routinely, 
7-12 days after tumour inoculation or vaccination 
draining inguinal LN were removed sterilely. 
Lymphocyte suspensions were prepared by first 
teasing LN with 20G needles and then pressing with 
the blunt end of a IO-ml plastic syringe in HBSS. 
Tumour irradiation 
The BL6 tumour cells were suspended in CM and 
maintained at 4°C. Cells were irradiated with 
l,OOO-32,000 cGy using a Gamma Cell 1000 irra- 
diator (500 cGy min’, Atomic Energy of Canada, 
Ltd). Irradiated tumour cells were then washed with 
HBSS x 2 and resuspended in HBSS for inoculation 
with an appropriate dose of C. parvum. 
In-vitro anti-CD3/IL-2 activation of LN cells 
Draining LN cells were stimulated in vitro by 
incubating approximately IO* cells in a 75 cm* tissue 
culture flask in 30 ml of CM with 2.5 ,ug ml-’ of anti- 
CD3 mAb at 37°C in 5% atmosphere for 2 days. In 
some experiments, 4 X IO6 LN cells were activated 
with immobilized anti-CD3 antibody in 24-well tissue 
culture plates. The cells were harvested, washed, 
and further cultured at 6x IO5 cells/well in 2 ml of 
CM containing 10 U ml-’ of IL-2 in 24-well plates for 
3 days. During this period of time, cells proliferated 
vigorously and the number increased, three- to six- 
fold. These anti-CD3/lL-2 activated cells were then 
harvested, washed and resuspended in HBSS for 
adoptive immunotherapy. 
Procedure for adoptive immunotherapy 
B6 mice were injected i.v. with 3-4 x lo5 BL6 tumour 
cells in 1 ml of HBSS to initiate pulmonary meta- 
stases. On day 3, anti-CD3/IL-2 activated draining LN 
cells were given i.v. to each mouse. Some mice 
were also treated with 15,000 U IL-2 in 0.5 ml HBSS 
i.p. twice a day for 4 days to enhance the in-vivo 
function of transferred cells. At this stage, all mice 
were eartagged and randomized. On day 14-17 of 
tumour growth the mice were killed, the lungs 
insufflated with Fekete’s solution, and pulmonary 
metastases enumerated as described previously [8]. 
Metastatic foci too numerous to count were 
assigned an arbitrary value of >250 because this 
was the largest number of tumour nodules that 
could be reliably enumerated. 
Statistical analysis 
The significance of differences in numbers of 
pulmonary metastases between groups was deter- 
mined by the Wilcoxon rank-sum test. Two sided P 
values of < 0.05 were considered significantly differ- 
ent. All groups consisted of at least five mice and no 
animal was excluded from the statistical analysis. 
RESULTS 
Draining LN response to progressive BL6 tumour 
growth 
We have previously reported that LN draining pro- 
gressive immunogenic methylcholanthrene-induced 
(MCA) sarcomas contain lymphocytes which can be 
secondarily activated in vitro to differentiate into 
therapeutic effector ceils for adoptive immuno- 
therapy [12-161. The BL6 tumour, being different 
from MCA sarcomas, has been characterized to be 
poorly or non-immunogenic and displays a highly 
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cal because a higher dose (50 pg) was ineffective. C. 
parvum inoculated without tumour cells did not 
induce pre-effector cells in the draining LN (data not 
shown). 
invasive growth pattern by spontaneously meta- 
stasizing after S.C. inoculation [19]. We therefore 
examined whether progressive BL6 tumour growth 
would elicit the development of pre-effector cells in 
tumour-draining LN. B6 mice were inoculated S.C. 
with lo6 viable BL6 tumour cells. Some animals 
were inoculated with viable tumour cells admixed 
with C, parvum, which was utilized as an immune 
adjuvant. Nine days later, draining inguinal LN were 
removed and activated by the anti-CD3/IL-2 culture 
method. This activation resulted in cells expanded 
approximately three- to six-fold. The activated cells 
were administered i.v. (5x lO’/mouse) into mice 
bearing 3-day established pulmonary metastases 
(Table 1). IL-2 was given (15,000 U i.p.) twice daily 
for 4 days starting on the day of cell transfer to pro- 
mote the in-vitro proliferation of the activated cells. 
This therapeutic regimen was well tolerated with 
no evidence of toxicity. Lungs were harvested 14 
days after tumour inoculation and pulmonary meta- 
stases enumerated in a blinded fashion. 
Tumourigenicity of irradiated BL6 melanomas 
Although C. parvum helped to stimulate a pre- 
effector cell response, the vaccination site showed 
progressive tumour growth and no systemic 
immunity was developed. Therefore, application of 
these approaches to generate immune cells in a 
clinical setting can be problematic. It is practical to 
establish a non-tumourigenic vaccine which would 
enable sensitization of pre-effector cells. 
In contrast to our previously reported experience 
with several immunogenic MCA sarcomas, the pro- 
gressive growth of the BL6 did not stimulate the 
sensitization of pre-effector cells in draining LN 
(Table 1) by evidence of the failure of anti-CD3/lL-2 
activated cells to mediate the regression of pulmon- 
ary metastases. However, the use of 12.5 ,ug of C. 
parvum at the initiation of tumour growth was found 
to elicit pre-effector cells in the draining LN which 
upon anti-CD3/lL-2 activation mediated potent anti- 
tumour reactivity. The dose of C. parvum was criti- 
One method commonly used to abrogate the 
tumourigenicity while maintaining immunogenicity 
of tumour cells is y-irradiation. Tumour cells treated 
with various doses of irradiation (l,OOO-16,000 cGy) 
were given S.C. to syngeneic mice (lO’/mouse) and 
the development of tumours was examined for up 
to 60 days (Table 2). Doses of 24000 cGy were 
found to be sufficient to inhibit active growth of the 
tumour. Similar results were obtained in the second 
experiment where IO’ tumour cells were tested 
(Table 2). 
Utilizing irradiated tumour cells, we investigated 
whether normal B6 mice could be systematically 
immunized against the BL6 tumour. Mice were 
inoculated S.C. in the flank with IO’ irradiated (12,000 
cGy) BL6 tumour cells admixed with various doses 
of C. parvum (0, 25, 50, 100, 200 pug). These animals 
Dose of C. parvum (pug) 
admixed with BL6 
tumour cells* 
Adoptive immunotherapy? 
Activated In-vivo Mean number pulmonary 
LN cells IL-2 metastases (SEM) 
Table 1. Adoptive immunotherapy of 
BL6 pulmonary metastases with anti- 
CD3/IL-2 activated LN cells derived 
from mice inoculated with viable 
tumour cells admixed with C. Darvum 
- - > 250 
+ > 250 
0 + + 209 (38) 
12.5 + + 8(6)$ 
50 + + 187(30) 
*Mice were inoculated S.C. in the flank with 1 O6 tumour cells admixed with 
various amounts of C. parvum in 0.1 ml of HBSS. Nine days later, inguinal LN 
cells were obtained and activated by the anti-CD3/IL-2 method. 
iActivated cells (5 X IO’) were administered i.v. into mice with 3-day established 
pulmonary metastases. IL-2 (15,000 U) was given i.p. twice daily for 4 days 
starting on the day of cell transfer. Lungs were harvested 14 days after tumour 
inoculation. 
$P< 0.05 compared with groups without treatment or treated with IL-2 only. 
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were challenged S.C. four weeks later, with lo6 
viable tumour cells in the opposite flank to deter- 
mine if systemic immunity was developed. Unlike 
immunization with previously defined MCA sarco- 
mas, such as MCA 105, MCA 106, MCA 205 and 
MCA 207 [I, 211, no demonstrable systemic immun- 
ity could be detected (data not shown). These 
observations further substantiated that the BL6 is a 
poorly immunogenic tumour. 
Draining LN response to irradiated BL6 tumour 
admixed with C. parvum 
A vaccine comprised of irradiated BL6 tumour cells 
and C. parvum was evaluated for its ability to elicit a 
pre-effector cell immune response in draining LN. 
Various numbers of irradiated (4,000 cGy) tumour 
cells were admixed with 12.5 ,ug of C. parvum and 
inoculated S.C. in the flank of B6 mice. Nine days 
later, draining inguinal LN were harvested for anti- 
CD3/IL-2 activation. The antitumour reactivity of the 
activated LN cells was assessed in the adoptive 
immunotherapy of 3-day established pulmonary 
metastases as previously described (Table 3). Mice 
inoculated with 1.2 x 1 O6 irradiated tumour cells and 
C. parvum did not elicit pre-effector cells because 
activated cells did not mediate tumour regression. In 
contrast, the same number of viable tumour cells 
admixed with 12.5 ,ug of C. parvurn was effective in 
eliciting immune pre-effector cells as demonstrated 
in Table 1. Therefore the difference in immuno- 
genicity between irradiated and viable tumour cells 





0 5/5 616 
1,000 5/5 - 
2,000 5/5 616 
4,000 O/5 Of6 
8,000 o/5 O/6 
16,000 O/5 O/6 
*Mice were inoculated SC. with IO6 or IO’ BL6 tumour 
cells in 0.5 of HBSS after various doses of irradiation. The 
incidence of tumour growth at the inoculation sites was 
observed over a 60-day period. 
appeared to be quantitative rather than qualitative. 
However, vaccines that consisted of a greater 
number of irradiated tumour cells (2 6 x 106) were 
capable of stimulating the sensitization of pre-effec- 
tor cells in the draining LN (Table 3). 
In another experiment, the effect of increased 
doses of tumour irradiation on the efficacy of the 
tumour vaccine was examined. B6 mice were inocu- 
lated S.C. in the flank with 12.5 pug C. parvum 
admixed with IO7 BL6 tumour cells which were 
treated with graded doses of irradiation 
(4,000-32,000 cGy). Nine days later, draining LN 
were harvested and activated by the anti-CD3/IL-2 
method. The antitumour reactivity of the activated 
cells was assessed again in the adoptive immuno- 
therapy of pulmonary metastases, as previously 
described (Table 4). All mice inoculated with 
irradiated tumour cells plus C. parvum developed 
immune pre-effector cells that mediated potent 
tumour regression after in-vitro activation. Hence, 
the dose of tumour irradiation did not seem to alter 
the immunogenicity of the tumour vaccine. More 
importantly, there was no evidence of progressive 
tumour growth at the site of vaccination. 
Table 3. Adoptive immunotherapy of BL6 pulmonary 
metastases with anti-CD3/lL-2 activated LN cells derived 
from tumour-vaccinated mice 
Number of irradiated tumour Adoptive immunotherapy+ 
cells admixed with 
C. parvum for vaccination* IL-2 Mean number of 
pulmonary 
metastases (SEM) 
A - > 250 
B + > 250 
c 1.2x105 + 189117) 
D 6x106 + 1 (I)]: 
E 3x10’ + O$ 
*Mice were inoculated S.C. in the flank with varying 
numbers of irradiated (4,000 cGy) BL6 tumour cells 
admixed with 12.5 pg C. parvum in 0.1 ml HBSS. Nine 
days after inoculation, inguinal LN cells were obtained and 
activated by the anti-CD3/lL-2 method. 
tActivated cells (5 x 107) were administered i.v. into mice 
with 3-day established pulmonary metastases. IL-2 (15,000 
U) was given i.p. twice daily for 4 days starting on the day 
of cell transfer. Lungs were harvested 14 days after 
tumour inoculation. 
Y’<O.O5 when compared with groups A, B and C. 
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Table 4. The amount of tumour irradiation does not alter 





in-vivo Mean number of pulmonary 
IL-2 metastases (SEM) 
A- - > 250 
B- + > 250 
c 4,000 + 12(3)* 
D 8,000 + 7(4)$ 
E 16,000 + 5(z)* 
F 32,000 + W2)$ 
*Mice were vaccinated S.C. in the flank with 1 x 1 O7 
irradiated (4,000-32,000 cGy) tumour cells admixed with 
12.5 pg. C parvum in 0.1 ml Ii&S. Nine days after 
inoculation, inguinal LN cells were obtained and activated 
by the anti-CD3/IL-2 method. 
tAdoptive immunotherapy of 3-day established BL6 
pulmonary metastases were performed as described in 
Table 3. 
jP<O.O5 compared with groups without treatment or 
treated with only IL-2. 
Kinetics of pre-effector cell sensitization after 
tumour vaccination 
The kinetics of pre-effector cell sensitization after 
tumour vaccination were examined. Groups of B6 
mice were inoculated S.C. with IO7 irradiated (4,000 
cGy) BL6 tumour ceils admixed with 12.5 pg C. 
parvum every few days so that draining LN could be 
harvested on the same day. During the observed 19- 
day period, there was a hyperplastic response in the 
draining LN which peaked on day 9 of vaccination 
and decreased thereafter (Fig. 1). The vaccine-drain- 
ing LN cells were activated by the anti-CDYIL-2 
culture method and subsequently assessed for anti- 
tumour reactivity in viva, as described (Table 5). 
Sensitized pre-effector cells were present as early as 
4 days after tumour vaccination and persisted to day 
14 before it began to diminish. By day 19, there 
were no detectable pre-effector cells in the draining 
LN. 
DlSCUSSlON 
Experimental evidence indicates that properly sensi- 
tized T-cells are extremely potent mediators of 
tumour rejection. Several laboratories have shown 
















Figure 1. Kinetics of pre-effector cell response after 
tumour vaccination. 56 mice were inoculated with 10’ 
irradiated (4,000 cGy) BL6 tumour cells admixed with 12.5 
pg C. parvum. There was no evidence of tumour growth 
during the lg-day observation period. A dramatic 
hyperplastic response in the draining LN was evident on 
day 9 after tumour vaccination. (---O-) CelIs/LN, 
(--•--_) tumour size. 
donors for immune cells which upon transfer, 
mediate the regression of localized or advanced 
tumour in syngeneic hosts [6-81. Also, animals 
successfully treated by the transfer of immune cells 
will reject subsequent challenges of the same 
tumour due to the establishment of systemic 
immunity in the host. However, there are formidable 
obstacles which need to be resolved before this 
approach can be applied to the therapy of malig- 
nancy in man. Foremost is the lack of reliable tech- 
niques to isolate and produce adequate numbers of 
tumour-reactive cells needed for adoptive immuno- 
therapy. Unlike animal studies, cancer patients 
usually do not have genetically identical counter- 
parts to immunize and generate donor immune 
cells. Therefore, application of adoptive immuno- 
therapy in man will require methods to obtain anti- 
tumour-reactive T-cells from the patient. In addition, 
human cancers have been postulated to be poorly 
immunogenic because of their spontaneous origin; 
and might not be analogous to experimentally 
induced animal tumours, many of which express 
tumour-specific antigens. 
To address these concerns, we have recently 
developed a culture method which promotes the 
differentiation and growth of therapeutic T-cells 
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Table 5. Kinetics of pre-effector cell 
sensitization in draining LN after 
tumour vaccination 
Days after vaccination when 
draining LN were harvested 
for anti-CDB/IL-2 activation* 
Adoptive immunotherapy+ 
IL-2 Mean number of pulmonary 
metastases (SEM) 
A _ > 250 
B - + 244(6) 
c 4 + 3(3)$5 
D 9 + 10(3)f5 
E 14 + 109(19)f 
F 19 + 214(15) 
*Mice were vaccinated S.C. with lo7 irradiated (4,000 cGy) BL6 tumour cells 
admixed with 12.5 pg C. parvum at various intervals prior to harvesting draining 
inguinal LN on the same day for activation by the anti-CD3/IL-2 method. 
iAdoptive immunotherapy of 3-day established BL6 pulmonary metastases was 
performed as described in Table 3. 
YcO.05 compared with groups A, B and F. 
§P < 0.05 compared with group E. 
derived from the tumour-bearing hosts for adoptive 
immunotherapy. This culture method involves the 
activation of tumour-draining LN cells with anti-CD3 
mAb for 2 days followed by expansion in IL-2 for 3 
days [14-161. Utilizing several immunogenic MCA- 
induced murine sarcomas, we found that activated 
cells had potent antitumour effects in adoptive 
immunotherapy experiments. In contrast, similarly 
activated normal lymphoid cells did not generate 
tumour-reactive effector cells. These findings 
suggest that progressive tumour growth stimulate 
an immune response developed in the draining LN 
cells, which we have termed ‘pre-effector cells’. This 
terminology was chosen because these cells, when 
freshly harvested, were not functionally active in 
adoptive immunotherapy and the generation of 
therapeutic effector cells required the secondary 
anti-CDS/IL-2 activation. 
The presence of pre-effector cells within the 
draining LN was critically dependent on the duration 
of tumour growth. Prolonged tumour growth 
resulted in the loss or inhibition of pre-effector cells 
[15]. Perhaps more importantly, there was a virtual 
absence of a pre-effector cell response in the drain- 
ing LN during the growth of a poorly immunogenic 
tumour, the BL6 melanoma (Table 1). However, the 
admixture of the bacterial adjuvant C. parvum at the 
time of BL6 inoculation did result in the develop- 
ment of pre-effector cells. The ability to elicit a pre- 
effector cell response against BL6 was highly 
dependent upon the amount of C. parvum used and 
was more effective at lower doses. The use of C. 
parvum did not result in growth inhibition or regres- 
sion of the BL6 tumour at the inoculation sites. 
These observations would be difficult to extrapolate 
for clinical application. We therefore explored the 
efficacy of a non-tumourigenic vaccine to trigger the 
pre-effector cell response. In order to define require- 
ments for such a vaccine, which can be applied to 
poorly immunogenic human cancers, we examined 
the use of irradiated BL6 tumour cells. We found 
that irradiation doses of 4,000 cGy or greater could 
effectively suppress tumourigenicity when IO6 or IO7 
cells were used as an inoculum (Table 2). As growth 
of viable BL6 tumour did not elicit a pre-effector cell 
response in the absence of C. parvum, we examined 
the use of varying numbers of irradiated tumour 
cells, admixed with a dose of C, parvum, to sensitize 
pre-effector cells. Although effective in stimulating a 
pre-effector response in draining LN (Table 3), con- 
siderably higher numbers of irradiated tumour cells 
were required than with viable tumour cells (Table 
4). The mechanisms by which C. parvum facilitated 
sensitization to BL6 tumour antigen are unknown; 
however, there have been several reports docu- 
menting the immune effects of this adjuvant. One 
possibility may be more effective antigen processing 
by macrophages because C. parvum is a known 
stimulator of macrophages [22]. Alternatively, C. 
parvum may have an adjuvant role by recruiting 
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lymphocytes to the tumour site with subsequent 
elaboration of cytokines that up-regulate an anti- 
tumour immune response [23-251. 
The pre-effector cell response to the tumour 
vaccination was also dependent upon the kinetics of 
vaccination. We found that pre-effector cells were 
detectable as early as 4 days after tumour vaccina- 
tion but rapidly declined from day 14 to 19 (Table 5). 
The suppression of the immune response could not 
be attributed to non-specific effects of tumour 
growth because there was no evidence of tumour 
growth at the vaccination site. One possible 
mechanism for this immune suppression may be the 
development of tumour suppressor cells. Our 
laboratory has previously demonstrated that the 
pre-effector cell response to growing subcutaneous 
tumour can be suppressed by the presence of 
visceral metastases [26]. In additional studies, we 
have been able to adoptively transfer splenocytes 
from visceral tumour-bearing mice into normal 
animals and subsequently identify suppression of 
the pre-effector cell response to a subcutaneous 
inoculation of tumour [27]. These observations 
indicate that the pre-effector cell response can be 
down-regulated by tumour-induced suppressor 
cells. Further studies to elucidate the mechanism of 
this suppression, and methods to overcome it, are 
clinically relevant. 
In other studies, we have further characterized 
the phenotypic and functional properties of 
activated pre-effector cells elicited by BL6 tumour 
and C. parvum (J. D. Geiger, manuscript in prepara- 
tion). Upon anti-CD3/lL-2 activation, LN cells drain- 
ing BL6 tumour admixed with C. parvum 
demonstrated a predominance of CD8+ cells com- 
pared with CD4+ T cells. Utilizing a 4-h 5’Cr release 
assay, these activated cells did not mediate in-vitro 
cytolysis of BL6 targets although these same targets 
were readily lysed by LAK cells. Despite the inability 
to lyse BL6 tumour in vitro, these activated LN cells 
mediated the specific regression of BL6 pulmonary 
metastases and not other immunologically distinct 
MCA sarcoma tumours. The mechanisms by which 
anti-CD3/lL-2 activated effector cells mediate in-vivo 
tumour regression are unknown but may involve the 
elaboration of cytokines [28], or further differentia- 
tion into cytolytic cells upon tumour interaction after 
adoptive transfer. 
The data presented in this report demonstrate the 
feasibility of generating therapeutic immune cells to 
a poorly immunogenic tumour with the aid of a non- 
tumourigenic vaccine. In this regard, the tumour 
vaccine serves to stimulate a pre-effector cell 
response which requires further in-vitro activation to 
develop into mature, functionally active therapeutic 
effector cells. We are currently exploring this 
approach in the treatment of patients with advanced 
malignancies. Initial observations have indicated that 
immune reactivity to autologous tumour is trans- 
ferred and tumour regression has been noted in 
some patients [29]. Future directions with this thera- 
peutic approach involve methods to enhance pre- 
effector cell sensitization. We have investigated the 
use of exogenously administered cytokines to deter- 
mine if pre-effector cell sensitization can be up- 
regulated. We have found that IL-l administration 
can significantly enhance the pre-effector cell 
response while there is no effect with exogenously 
administered IL-2 [30]. In addition, we found that the 
administration of TNFa will down-regulate the pre- 
effector cell response [31]. Another manipulation, 
which may lead to an enhanced pre-effector cell 
sensitization, is the use of genetically modified 
tumours. Several recent studies have demonstrated 
that the transduction of murine tumour cells with 
genes encoding cytokines (i.e. IL-2, IL-4, TNFa) alter 
the immunological properties of tumours [32-341. 
This may provide an alternate approach to develop- 
ing a pre-effector cell response to poorly immuno- 
genic tumours which our laboratory is currently 
investigating [35]. 
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